Mei-Li Wen

Discovery of <i>N</i>-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Louis J. Lombardo, Francis Y. Lee, Ping Chen et al. · Journal of Medicinal Chemistry · 2004 · 1.3K citations · Full text

Drug Target, Preclinical Assays, Pharmacotherapy +19

Tumor Development by Transgenic Expression of a Constitutively Active Insulin-Like Growth Factor I Receptor

Joan M. Carboni, Adrian V. Lee, Darryl L. Hadsell et al. · Cancer Research · 2005 · 203 citations · Full text

Receptor Antagonists, Cell Proliferation, Tumor Biology +16

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Feng Luo, Zheng Yang, Amy Camuso et al. · Clinical Cancer Research · 2006 · 149 citations

Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors

Ashvinikumar V. Gavai, Claude Quesnelle, Derek Norris et al. · ACS Medicinal Chemistry Letters · 2015 · 88 citations · Full text

Solid Tumors, Pharmacotherapy, Tumor Biology +18

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor

Feng Luo, Yu Chen Barrett, Zheng Yang et al. · Cancer Chemotherapy and Pharmacology · 2008 · 50 citations · Full text

Hematological Malignancy, Tumor Biology, Drug Targeting +14